SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000886163-23-000075
Filing Date
2023-10-18
Accepted
2023-10-17 19:24:26
Documents
13
Period of Report
2023-10-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lgnd-20231012.htm   iXBRL 8-K 33390
2 EX-10.1 edgarizedcitiligandcredita.htm EX-10.1 1809180
  Complete submission text file 0000886163-23-000075.txt   2230952

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lgnd-20231012.xsd EX-101.SCH 1911
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lgnd-20231012_lab.xml EX-101.LAB 24134
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lgnd-20231012_pre.xml EX-101.PRE 12518
7 EXTRACTED XBRL INSTANCE DOCUMENT lgnd-20231012_htm.xml XML 2742
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

IRS No.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33093 | Film No.: 231330645
SIC: 2834 Pharmaceutical Preparations